Devices & Tech
FDA Clears Restylane Contour for Temple Hollowing — Galderma Expands Filler Anatomy
New indication targets age-related volume loss in the temple area, a growing patient demand.
Photo: Opt Lasers from Poland / Pexels
AI Inside MedSpa Intelligence · Jun 26, 2026
Galderma has received FDA approval for Restylane Contour for the correction of temple hollowing, expanding the approved uses of its popular filler line. Temple volume loss is a hallmark of facial aging and a frequent patient complaint, particularly among practitioners seeking to offer comprehensive facial rejuvenation.
Restylane Contour, designed with a thicker gel consistency for structural support, is now cleared for this specific anatomical indication. The approval gives practices another tool to address age-related volume loss and compete with Allergan's expanding Juvéderm portfolio. For practices already using Restylane products, this represents a natural line extension.
Restylane Contour now cleared for temple hollowing correction, addressing a common sign of facial aging.
Source: original report ↗
Frequently asked questions
What is Restylane Contour FDA approved for now?
Restylane Contour is now FDA-approved for the correction of temple hollowing, addressing age-related volume loss in the temple area. This new indication expands Galderma's approved uses for the Restylane filler line and gives practitioners a dedicated tool for comprehensive facial rejuvenation.
Why is temple volume loss a common patient concern?
Temple volume loss is a hallmark of facial aging and a frequent patient complaint, particularly as patients seek comprehensive facial rejuvenation. Addressing hollowing in this area has become growing patient demand for aesthetic practices.
What makes Restylane Contour different from other Restylane products?
Restylane Contour is designed with a thicker gel consistency specifically for structural support, making it well-suited for areas requiring more robust volume replacement like the temples. This formulation distinguishes it from other products in the Restylane line.
How does Restylane Contour compete with Juvéderm for temple treatment?
The new temple hollowing indication gives Restylane Contour a direct competitive advantage against Allergan's expanding Juvéderm portfolio. For practices already using Restylane products, this represents a natural line extension that allows them to offer comprehensive temple rejuvenation options.
Is temple hollowing treatment a new service for med spas?
While temple volume loss has long been recognized as part of facial aging, the FDA approval of Restylane Contour specifically for this indication provides practices with a validated, approved option to market this service. This approval reflects growing patient demand for temple rejuvenation as part of comprehensive facial aesthetics.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief every morning. The owners who read it never get blindsided.
Get the edge · $20/mo Join the owners who run ahead of the industry. Cancel anytime, one click.
